Seasoned investor & business operator with over two decades of investing, C-level management, business development & R&D experience. Has managed 50+ financing, investments, partnering, R&D collaborations & acquisitions, totaling over $2 Billion in transaction value. Leverages deep scientific background, thought leadership & robust network to catalyze portfolio growth. Serves as Strategic Advisor & Investment Mentor for The New York State Center for Advanced Technology & Vanderbilt University. Reviewer & Board Director of 10+ healthcare companies, federal funding agencies & research journals. Received D.Phil. (PhD) from Oxford University, Visiting Scientist at Cold Spring Harbor Laboratory (CSHL). Authored 20+ research articles on precision medicine & gene-editing technologies in Oncology, CNS disorders & Rare Diseases.

• Founded investment & advisory firm specializing in venture capital & private equity fund operations, portfolio construction, asset prioritization, risk management strategies, strategic planning, BD&L, commercialization strategies, co-promoting, spin-offs, pricing & reimbursement strategies, market access strategies, clinical & financial due diligence, valuation & financial modeling, deal structuring, M&A & strategic partnerships. Guided strategy & business operations as Board Member & advisory committee member for several successful biopharma, medtech & healthcare technology companies: ElevateBio, Fractyl Health (NASDAQ: GUTS), Roivant Sciences (NASDAQ: ROIV), AlloVir (NASDAQ: ALVR), BridgeBio (NASDAQ: BBIO), SQZ Biotech (NYSE: SQZ), Atomwise, Cullinan Therapeutics (NASDAQ: CGEM).

• Built & rapidly grew top decile performing healthcare & life sciences investment portfolio as Portfolio Manager (PM) at AIG Investments, a global financial institution. Executed transactions totaling over $1Billion in enterprise value across venture capital, private equity, credit, structured finance, & growth equity. Devised & implemented investment strategies that produced 68% IRR & 3x MOIC, outperforming nearly all asset classes prior to strategic exit.

• Co-founded alternative investment fund focused on healthcare, life sciences & technology, managing investments across capital structure. Built & coached teams in orchestrating & executing all phases of investment process - deal sourcing, due diligence, negotiations, & portfolio monitoring to ensure adherence to risk tolerance & compliance standards.

• Managed diverse cross-functional teams across corporate finance, M&A, business development, investor relations & clinical operations as Global Chief Business Officer (CBO) at Oryzon, a public biotech company. Spearheaded portfolio optimization strategies, target product profile, BD&L, regulatory, budget, product development & commercialization, market access strategies, valuation negotiations & capital raising strategies.

• Built close network with life sciences & technology companies, VCs, hedge funds, institutional and strategic investors, family offices, angel investors, philanthropic foundations, biomedical accelerators, investment banks, & academic institutions.

To meet with Sai, or any of our excellent mentors, please fill out this interest form.